Indirubin-3′-monoxime inhibits β-amyloid-induced neurotoxicity in neuroblastoma SH-SY5Y cells

Neuroscience Letters

Volumn 450, Issue 2, 2009, Pages 142-146

  Zhang, Shugang ^a   Zhang, Yingdong ^a   Xu, Ligang ^a   Lin, Xingjian ^a   Lu, Jie ^a   Di, Qing ^a   Shi, Jingping ^a   Xu, Jun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

A ; Alzheimer's disease; Indirubin 3 monoxime; Neuronal apoptosis; Tau protein hyperphosphorylation

Indexed keywords

AMYLOID BETA PROTEIN; DNA; INDIRUBIN; TAU PROTEIN; AMYLOID BETA PROTEIN (25 35); AMYLOID BETA-PROTEIN (25-35); ANNEXIN; INDIRUBIN 3' MONOXIME; INDIRUBIN-3'-MONOXIME; INDOLE DERIVATIVE; OXIME; PEPTIDE FRAGMENT; SERINE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; METABOLISM; NEUROBLASTOMA; NICK END LABELING; PATHOLOGY; PHOSPHORYLATION; TIME; TUMOR CELL LINE;

AMYLOID BETA-PROTEIN; ANNEXINS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; IN SITU NICK-END LABELING; INDOLES; NEUROBLASTOMA; OXIMES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; SERINE; TAU PROTEINS; TIME FACTORS;

EID: 58149356984     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.11.030     Document Type: Article

References (25)

1. Alvarez A., Munoz J.P., and Maccioni R.B. A Cdk5-p35 stable complex is involved in the beta-amyloid-induced deregulation of Cdk5 activity in hippocampal neurons. Exp. Cell. Res. 264 (2001) 266-274
2. Becker E.B., and Bonni A. Cell cycle regulation of neuronal apoptosis in development and disease. Prog. Neurobiol. 72 (2004) 1-25
3. Camins A., Verdaguer E., Folch J., Canudas A.M., and Pallas M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect. 19 (2006) 453-460
4. Chen X., Huang T., Zhang J., Song J., Chen L., and Zhu Y. Involvement of calpain and p25 of CDK5 pathway in ginsenoside Rb1's attenuation of beta-amyloid peptide25-35-induced tau hyperphosphorylation in cortical neurons. Brain Res. 1200 (2008) 99-106
5. Cheung Z.H., and Ip N.Y. Cdk5: mediator of neuronal death and survival. Neurosci. Lett. 361 (2004) 47-51
6. Choi Y., Kim H.S., Shin K.Y., Kim E.M., Kim M., Park C.H., Jeong Y.H., Yoo J., Lee J.P., Chang K.A., Kim S., and Suh Y.H. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32 (2007) 2393-2404
7. D'Souza I., Poorkaj P., Hong M., Nochlin D., Lee V.M., Bird T.D., and Schellenberg G.D. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5598-5603
8. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., and Sato K. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6370-6375
9. Jamsa A., Hasslund K., Cowburn R.F., Backstrom A., and Vasange M. The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation. Biochem. Biophys. Res. Commun. 319 (2004) 993-1000
10. Jarvis K., Assis-Nascimento P., Mudd L.M., and Montague J.R. Beta-amyloid toxicity and reversal in embryonic rat septal neurons. Neurosci. Lett. 423 (2007) 184-188
11. Johnson K., Liu L., Majdzadeh N., Chavez C., Chin P.C., Morrison B., Wang L., Park J., Chugh P., Chen H.M., and D'Mello S.R. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3′ substituted indolones as a scaffold for the development of neuroprotective drugs. J. Neurochem. 93 (2005) 538-548
12. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., and Meijer L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?. J. Biol. Chem. 276 (2001) 251-260
13. Marko D., Schatzle S., Friedel A., Genzlinger A., Zankl H., Meijer L., and Eisenbrand G. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer 84 (2001) 283-289
14. Monaco III E.A., and Vallano M.L. Role of protein kinases in neurodegenerative disease: cyclin-dependent kinases in Alzheimer's disease. Front Biosci. 10 (2005) 143-159
15. Moon M.J., Lee S.K., Lee J.W., Song W.K., Kim S.W., Kim J.I., Cho C., Choi S.J., and Kim Y.C. Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg. Med. Chem. 14 (2006) 237-246
16. Nishida H., Kushida M., Nakajima Y., Ogawa Y., Tatewaki N., Sato S., and Konishi T. Amyloid-beta-induced cytotoxicity of PC-12 cell was attenuated by Shengmai-san through redox regulation and outgrowth induction. J. Pharmacol. Sci. 104 (2007) 73-81
17. Peng Y., Xing C., Lemere C.A., Chen G., Wang L., Feng Y., and Wang X. l-3-n-Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells. Neurosci. Lett. 434 (2008) 224-229
18. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., and Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 6364-6369
19. Shen Y., He P., Zhong Z., McAllister C., and Lindholm K. Distinct destructive signal pathways of neuronal death in Alzheimer's disease. Trends Mol. Med. 12 (2006) 574-579
20. Tomidokoro Y., Ishiguro K., Harigaya Y., Matsubara E., Ikeda M., Park J.M., Yasutake K., Kawarabayashi T., Okamoto K., and Shoji M. Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice. Neurosci. Lett. 299 (2001) 169-172
21. Vila M., and Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 4 (2003) 365-375
22. Wang W., Redecker C., Yu Z.Y., Xie M.J., Tian D.S., Zhang L., Bu B.T., and Witte O.W. Rat focal cerebral ischemia induced astrocyte proliferation and delayed neuronal death are attenuated by cyclin-dependent kinase inhibition. J. Clin. Neurosci. 15 (2008) 278-285
23. Xiao Z., Hao Y., Liu B., and Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma 43 (2002) 1763-1768
24. Xie Y., Liu Y., Ma C., Yuan Z., Wang W., Zhu Z., Gao G., Liu X., Yuan H., Chen R., Huang S., Wang X., Zhu X., Mao Z., and Li M. Indirubin-3′-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci. Lett. 367 (2004) 355-359
25. Zhang M., Li J., Chakrabarty P., Bu B., and Vincent I. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am. J. Pathol. 165 (2004) 843-853